2023

Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine

Front. Psychiatry 14:1259041. doi: 10.3389/fpsyt.2023.1259041
Loftis J.M., Ramani S., Firsick E.J., Hudson R., Le-Cook A., Murnane K.S., Vandenbark A., Shirley R.L.
2022

"Near Cure" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct

Cellular Immunology, 2022:378, 104561
Vandenbark A.A., Meza-Romero R., Wiedrick J., Gerstner G., Seifert H., Kent G., Piechycna M., Benedek G., Bucala R., Offner H.
2019

A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury

Journal of Neuroinflammation, 16, 14 (2019)
Vandenbark A.A., Meza-Romero R., Benedek G., Offner H.
2014

RTL treatment improves neurological outcomes in the presence of tPA in experimental ischemic stroke

Translational Stroke Research, 2014, 5:612–617
2014

HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis

Journal of Immunology, 2014, 192, 4164–4173
2014

Traumatic brain injury causes selective, CD74-dependent peripheral lymphocyte activation that exacerbates neurodegeneration

Acta Neuropathologica Communications, 2014, 2, 143–153
2013

Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects

European Journal of Immunology, 2013, 43, 1309–1321
2013

A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance

Journal of Autoimmunity, 2013, 40C, 96:10
2013

Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction

PLoS One, 2013;8:e56306
Loftis J.M., Wilhelm C.J., Vandenbark A.A., Huckans M.